COPD: Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Expression and Predictive Value of Angiopoietin-2 in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.","authors":"Ruiqin Ni, Mengrong Xie, Jingying Zhang, Mingmei Zhong","doi":"10.1080/15412555.2025.2512749","DOIUrl":"https://doi.org/10.1080/15412555.2025.2512749","url":null,"abstract":"<p><p>Clear and effective treatment for pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD) has not been established, and thus promptly identifying patients with PH is of particular importance. In this study, by comparing Angiopoietin-2 expression in patients with COPD and COPD-PH, we analysed the risk factors of PH and evaluated the predictive value of these in PH. Therefore, this prospective study selected COPD of patients as research subjects, which were divided into COPD and COPD-PH groups according to whether they were complicated with PH. Lung function, general laboratory index, N-terminal pro brain b-type natriuretic peptide (NT-proBNP), Angiopoietin-2, and other cytokines levels were compared between the two groups, and the risk factors of COPD-PH were explored through multivariate binary regression analysis. Lastly, receiver operating characteristic curve was used in evaluating the predictive value of risk factors for COPD-PH. The results show that the COPD-PH group has higher Angiopoietin-2, logistic analysis showed that Angiopoietin-2, NT-proBNP, age, and FEV1%pred were independent risk factors for COPD-PH and had high predictive value for COPD-PH. The AUROC for Angiopoietin-2 and NT-proBNP for predicting COPD-PH were 0.646 and 0.751. When Angiopoietin-2 ≥ 39.55 pg/ml, NT-proBNP ≥ 134.03 pg/ml, the sensitivity for COPD-PH prediction was 44.7 and 93.6%, respectively, and the specificity rates were 83.1 and 49.2%, respectively. When Angiopoietin-2 was combined with NT-proBNP, enhanced the AUROC to 0.766, exceeding Angiopoietin-2 alone, which may be useful in the prediction of COPD-PH.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2512749"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Experience of Automated Home Oxygen Therapy for Patients With COPD - A Qualitative Study.","authors":"Linette Marie Kofod, Louise Bolvig Laursen, Elisabeth Westerdahl, Ejvind Frausing Hansen, Barbara Cristina Brocki, Morten Tange Kristensen, Dorthe Gaby Bove","doi":"10.1080/15412555.2025.2477243","DOIUrl":"10.1080/15412555.2025.2477243","url":null,"abstract":"<p><p>The present study included the first patients with COPD on long-term oxygen therapy who experienced second-by-second oxygen adjustments in their homes based on oxygen saturation. A device capable of automatically titrating the patient's oxygen was installed in the patients' home aiming at increasing the time spent within target saturation. We explored patients' experiences with this automated home oxygen titration, focusing on how maintaining target saturation affected daily life. Semi-structured interviews were conducted with eight men and four women after installation. Systematic text condensation was used in the analysis. Three main themes emerged from patient narratives: (1) \"This is my life\" - Patients preferred maintaining stable oxygen saturation, associating hypoxemia with dyspnea, discomfort, and difficulties with daily tasks. (2) \"Getting the oxygen, I need\" - Many patients reported improved ability to perform daily activities when oxygen was automatically adjusted. (3) \"New technology gives hope for my life\" - Patients expressed optimism about the potential of home-based technology, offering suggestions to improve usability, mainly by reducing concentrator noise. Our findings suggested high acceptability of the automated oxygen in the patients' home, as they believed it to increase the time spend with sufficient oxygen, especially during daily activities. Integrating patient insights is essential for implementation and acceptance of automated home oxygen therapy.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2477243"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of ABCA1 in Chronic Obstructive Pulmonary Disease.","authors":"Ying Gu, Xiaoqing Bi, Xiaofei Liu, Qingqing Qian, Yiqiong Wen, Shu Hua, Qiaoli Fu, Yuanyuan Zheng, Shibo Sun","doi":"10.1080/15412555.2025.2493701","DOIUrl":"https://doi.org/10.1080/15412555.2025.2493701","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is one of the common chronic respiratory diseases, which causes a heavy burden to patients and society. Increasing studies suggest that ABCA1 plays an important role in COPD. ABCA1 belongs to a large class of ATP-binding (ABC) transporters. It is not only involved in the reverse transport of cholesterol, but also in the regulation of apoptosis, pyroptosis, cellular inflammation and cellular immunity. Meanwhile, ABCA1 is involved in several signaling pathways, such as SREBP pathway, LXR pathway, MAPK pathway, p62/mTOR pathway, CTRP1 pathway and so on. In addition, the ABCA1 participates in the disorder of lipid metabolism in COPD by regulating the formation of RCT and HDL, regulates the inflammation of COPD by removing excess cholesterol in macrophages, and promotes the differentiation of COPD phenotype into emphysema type. Accordingly, the ABCA1 may be a therapeutic target for COPD.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2493701"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics in COPD: The Road is Still Long and Winding.","authors":"Konstantinos Kostikas, Athena Gogali","doi":"10.1080/15412555.2025.2467657","DOIUrl":"https://doi.org/10.1080/15412555.2025.2467657","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2467657"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Association of Lipid-Lowering Drug Target Genes with Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study.","authors":"Hao Luan, Tianhua Wang, Rui Wang, Yu Wang, Yu Liu, Wenru Sheng, Jiaqi Guo, Haotian Ji, Xiufeng Liu, Xiqing Xue, Yiider Tseng","doi":"10.1080/15412555.2025.2513601","DOIUrl":"https://doi.org/10.1080/15412555.2025.2513601","url":null,"abstract":"<p><p>The role of lipid-lowering drugs in chronic obstructive pulmonary disease (COPD) is controversial in clinical studies. This study aimed to explore the causal relationship between lipid-lowering drugs and COPD from a genetic perspective, and to evaluate the potential effects of this relationship. Four hundred and thirty-one lipid-related phenotypes and two COPD datasets were obtained from Genome-Wide Association Studies (GWAS) and analysed together using Mendelian randomization (MR). Genetic variants associated with genes encoding targets of lipid-lowering drugs were extracted from the Global Lipid Genetics Consortium. Expression quantitative trait loci data in relevant tissues were adopted to validate lipid-lowering drug targets that reached significance. We found that four lipid abnormalities were associated with COPD risk. Genetically proxied inhibition of HMG-CoA reductase (HMGCR) and PCSK9 is associated with an increased risk of COPD. And there is a significant MR correlation between increased whole blood HMGCR expression and COPD. HMGCR and PCSK9 inhibitors are associated with onset of COPD, lung function, and COPD-associated infections. Mediation analyses were performed to explore potential mediators of how genetically proxied inhibition of HMGCR and PCSK9 influences the risk of COPD through different immune cell phenotypes and inflammatory factor levels. Our findings indicate a potential link between the use of HMGCR and PCSK9 inhibitors and increased risk of COPD and exacerbation of COPD phenotypes. This suggests effects beyond LDL-C modulation, potentially involving immune cell function and inflammatory factors.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2513601"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Chronic Obstructive Pulmonary Disease in China: A Global Burden of Disease Study on Temporal Trends, Risk Factor Contributions, and Projected Disease Burden from 1990 to 2030.","authors":"Jiaman Liao, Longsheng Zeng, Xueliang Huang, Hao Huang, Cuina Shen, Jing Li, Yiqiang Zhan","doi":"10.1080/15412555.2025.2531016","DOIUrl":"https://doi.org/10.1080/15412555.2025.2531016","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is a major public health issue in China, but comprehensive studies on its long-term trends, risk factors, and future projections are limited. This study aimed to assess the COPD burden in China from 1990 to 2021, analyze risk factor contributions across demographic subgroups, and project future trends through 2030 to inform public health interventions. Data from the Global Burden of Disease Study 2021 were analyzed for incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Joinpoint regression was used to calculate age-standardized rates, population attributable fractions (PAFs) assessed risk factor contributions, and ARIMA modeling projected future trends. From 1990 to 2021, the age-standardized incidence, prevalence, mortality, and DALYs rates of COPD showed a declining trend, while the absolute burden increased due to population growth and aging. Men had a higher overall disease burden, but since 2015, women have shown higher age-standardized prevalence. The highest burden was observed in the ≥80 age group, with a worrying rise in age-standardized mortality in the 20-24 age group. Smoking was a major risk factor for men, while ambient particulate matter pollution had a greater impact on women and younger adults (30-34 years). Projections suggest a decreasing trend for most age groups, while the 30-39 and ≥80 age groups will experience an increase in age-standardized incidence rates. These findings highlight the need for targeted public health strategies focusing on tobacco control, air pollution, and climate-related exposures, with emphasis on age and sex differences.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2531016"},"PeriodicalIF":2.2,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Function Decline in COPD - Relations to Changes in Symptom Burden, Inflammation, and Comorbidities.","authors":"Juan Wang, Björn Ställberg, Maria Hårdstedt, Kristina Bröms, Margareta Gonzalez Lindh, Amir Farkhooy, Andreas Palm, Karin Lisspers, Marieann Högman, Andrei Malinovschi","doi":"10.1080/15412555.2025.2525433","DOIUrl":"https://doi.org/10.1080/15412555.2025.2525433","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to improve the knowledge on the associations between comorbidities, symptom burden, inflammatory biomarkers and lung function deterioration in chronic obstructive pulmonary disease (COPD).</p><p><strong>Materials and methods: </strong>Of the 572 COPD subjects initially included in the 2014-2016 Tools for Identifying Exacerbations in COPD study in Sweden, 228 had lung function data at the 7-year follow-up. Symptom burden was assessed by the modified British Medical Research Council scale of dyspnoea (mMRC), the COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ). Relative lung function decline was assessed as decline in forced expiratory volume in one second (FEV₁) from baseline/year.</p><p><strong>Results: </strong>Lower baseline symptom burden (mMRC, CAT and CCQ), higher FEV₁ and FEV₁% predicted, higher forced vital capacity (FVC) and having atrial fibrillation were associated with larger absolute FEV₁ decline. Associations were found for having atrial fibrillation at baseline and larger relative FEV₁ decline (Beta = -1.60, <i>p</i> = 0.005). Increased symptom burden (value at follow-up minus value at baseline), assessed by mMRC, CAT and CCQ, was positively associated with both larger absolute FEV₁ decline (mMRC: Beta = 6.4, <i>p</i> = 0.009; CAT: Beta = 1.63, <i>p</i> = 0.002; CCQ: Beta = 10.6, <i>p</i> < 0.001) and larger relative FEV₁ decline (mMRC: Beta = 0.44, <i>p</i> = 0.003; CAT: Beta = 0.13, <i>p</i> < 0.002; CCQ: Beta = 0.82, <i>p</i> < 0.001). Moreover, an increase in C-reactive protein (CRP) levels at follow-up was related to larger, both absolute and relative, FEV₁ decline (Beta = 1.14, <i>p</i> = 0.031 and Beta = 0.07, <i>p</i> = 0.019, respectively).</p><p><strong>Conclusions: </strong>Changes in systemic inflammation and symptom burden between two visits were positively associated with a 7-year lung function decline.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2525433"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory Clinicians' Views on Offering \"Rescue Packs\" to Patients Discharged After COPD Exacerbation: Qualitative Interview Study.","authors":"Karolina Kuberska, Graham Martin, John R Hurst, Mona Bafadhel","doi":"10.1080/15412555.2025.2524346","DOIUrl":"https://doi.org/10.1080/15412555.2025.2524346","url":null,"abstract":"<p><p>\"Rescue packs\" for COPD exacerbations, consisting of a course of antibiotics and steroids, have become part of self-management strategies for many patients living with COPD. Currently, in the UK, rescue packs are guideline-recommended but not routinely offered on hospital discharge. They are, however, commonly prescribed by primary care teams. This study examined hospital-based respiratory clinicians' views on offering patients rescue packs following hospitalisation for COPD exacerbations. We conducted 24 individual and joint semi-structured interviews <i>via</i> telephone or videocall with 30 clinicians (respiratory consultants, respiratory registrars and specialist nurses) in 20 UK hospitals to understand variation in practice around, and views on, offering rescue packs to discharged COPD patients. Interview data were analysed using the constant comparative method. Clinicians' views on offering rescue packs were a mixture of concerns and recognition of potential benefits. Concerns included antimicrobial resistance, individual overuse of antibiotics, and potential side effects of steroids, especially in patients with poorer understanding of their own condition, with lower self-management skills, or who found it difficult to access primary care. Recognised benefits included the potential to prevent future exacerbations, empowering patients by supporting COPD self-management, and circumventing the difficulties of securing an urgent primary care appointment. There was a consensus that supporting patients in self-management of COPD was key to effective care. Given the increasing role of self-management for patients living with COPD, it is vital to ensure that patients are able to appropriately use rescue packs.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2524346"},"PeriodicalIF":2.2,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use, Effectiveness, and Safety of Inhaler Devices for LABA/LAMA Fixed-Dose Combinations in Patients with COPD.","authors":"Sara Lopes, Maria Lucia Marino, Filomena Fortinguerra, Nera Agabiti, Valeria Belleudi, Francesco Trotta","doi":"10.1080/15412555.2025.2506548","DOIUrl":"10.1080/15412555.2025.2506548","url":null,"abstract":"<p><p>In Italy, long-acting bronchodilator (LABA/LAMA) fixed-dose combinations are widely used for treating chronic obstructive pulmonary disease (COPD). These medications are available in various inhaler devices, but clinical guidelines do not recommend a specific device, leaving the choice to clinicians based on patient needs. To date, no studies have directly compared the effectiveness and safety of different LABA/LAMA devices. This retrospective observational study evaluated the utilization, effectiveness, and safety of LABA/LAMA inhaler devices in COPD patients in the Lazio region, representing about 10% of Italy's population. Patients aged 45 and older who initiated LABA/LAMA treatment between January 2017 and December 2019 were included. The devices analyzed were dry powder inhalers (DPI) capsule/strip (DPI-<i>t</i>, reference group), DPI with a reservoir (DPI-r), and soft mist inhalers (SMI). The study identified 12,346 eligible patients, with over 80% having prior COPD drug use. Of these, 53.2% used DPI-<i>t</i>, 19.7% DPI-r, and 27.1% SMI. No significant differences in severe exacerbations, mortality, pneumonia, or cerebro-cardiovascular events were observed among the devices. Hazard ratios for key outcomes (e.g., severe exacerbations, mortality) showed overlapping confidence intervals across device types, suggesting no device offered superior effectiveness or safety. This is the first study to assess LABA/LAMA device use in real-world clinical practice for COPD. Findings suggest therapeutic equivalence among devices, supporting flexibility in prescribing. Further research is needed to inform cost-effective prescribing policies for LABA/LAMA therapies.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2506548"},"PeriodicalIF":2.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis Should Not Be Simply Conducted By Default: Biologic Therapy for Chronic Obstructive Pulmonary Disease.","authors":"Jean Bourbeau, Claudia LeBlanc, Bryan Ross, Darcy Marciniuk","doi":"10.1080/15412555.2025.2501548","DOIUrl":"https://doi.org/10.1080/15412555.2025.2501548","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2501548"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}